Elektrofi has secured funding to support the advance of candidates based on its drug delivery technology into the clinic. Having landed deals with companies including Argenx and Takeda, the biologics ...
Oct 1 (Reuters) - Halozyme Therapeutics (HALO.O), opens new tab said on Wednesday it has agreed to acquire privately held Elektrofi in a deal worth up to $900 million to expand its drug delivery ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Financing led by Novo Holdings, RA Capital Management, Royalty Pharma, SR One, and TPG Life Sciences Innovations, with participation from 16 additional new and existing investors Proceeds will be used ...
Halozyme paid $750 million in cash to acquire its subcutaneous drug delivery peer Elektrofi last fall. (beast01/iStock/Getty Images Plus) As drugmakers strive to fine-tune the delivery of their ...
BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma A/S, a global leader in medical dermatology and Elektrofi, a Boston- based biotechnology company focused on drug formulation and delivery innovations, ...
BOSTON--(BUSINESS WIRE)--Elektrofi, a Boston-based biotechnology company focused on drug formulation and delivery innovations, today announced the completion of a $40 million Series B financing round.
Halozyme Therapeutics has agreed to acquire US-based Elektrofi in a deal worth up to $900m, which will see it add microparticle capabilities to its portfolio of drug delivery technologies. Halozyme ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results